Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is an open label single site Phase II clinical trial to identify a potentially promising
therapy dose for Sunitinib malate. The study drug will be taken orally once daily on days 1
through 28 of each 42 day cycle. Treatment will be continued until there is either disease
progression or cumulative/acute toxicity.
All patients with unresectable or metastatic soft tissue sarcoma (STS): leiomyosarcoma,
liposarcoma, fibrosarcoma, and malignant fibrous histiocytoma (MFH) seen at the Moffitt
Cancer Center will be screened for eligibility to be enrolled in the study.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute